ADtouch Results: Hand and Foot Eczema Responds Well to Lebrikizumab Medscape Source link
US FDA Approves Less Frequent Lebrikizumab Dosing in AD The Dermatology Digest Source link
Significance of New Phase 3 Lebrikizumab Trial in Nummular Eczema, With Kilian Eyerich, MD, PhD HCPLive Source link
Lebrikizumab plus TCS shows sustained disease control in refractory atopic dermatitis Hospital Healthcare Europe Source link